CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Clinical trial NCT02529813 · COMPLETED

Trial details

NCT number: NCT02529813
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Biphenotypic Leukemia Acute Lymphoblastic Leukemia Blasts 5 Percent or More of Bone Marrow Nucleated Cells CD19 Positive Minimal Residual Disease Non-Hodgkin Lymphoma Small Lymphocytic Lymphoma Stage III Chronic Lymphocytic Leukemia Stage IV Chronic Lymphocytic Leukemia

Start date: 2015-12-16
Primary completion: 2021-11-08
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.